Cancer Survivorship Trials
Metabolic Syndrome Following Transplant for Leukemia (2357)
Metabolic Syndrome Following Transplant for Leukemia
||Leukemia Survivors and their Siblings
This clinical trial studies the relationship between insulin resistance, growth hormone deficiency and other mediators of insulin resistance, with the development of metabolic syndrome in a sample of adolescent and young adult survivors of childhood leukemia who underwent HCT; to compare the prevalence of metabolic syndrome in HCT survivors to the general population; and to compare specific measures of insulin resistance and metabolic syndrome to age/sex matched control subjects that have been studied in a similar fashion.
Seattle Children's Hospital
Eligibility Criteria (must meet the following to participate in this study)
- Survivors after HCT treated at Fairview-University Medical Center or the FHCRC/SCCA or sibling of HCT survivor.
- Primary diagnosis of hematologic malignancy.
- Diagnosed with their disease at age 21 years or younger.
- Survived a minimum of 2 years post-transplant and be in remission from their leukemia.
- Age ≥ 9 at time of study participation if recruited from Minnesota site.
- Age > 9 and <22 at time of study participation if recruited from FHCRC/SCCA site.
Exclusions (conditions that would prevent participation in this study)
- Eligibility will not be restricted by race or sex.
- Any women currently pregnant will not be eligible, but may participate 3 or more months after the end of her pregnancy if the study is still ongoing.
May 20, 2011
Access protocol and consent forms at Fred Hutchinson Cancer Research Center
Disclaimer: We update this information regularly. However, what you read today may not be completely up to date.
- Talk to your health care providers first before making decisions about your health care.
- Whether you are eligible for a research study depends on many things. There are specific requirements to be in research studies. These requirements are different for each study.